FDA announces voluntary recall
of several medications containing valsartan
Food and Drug Administration voluntary recall announcement of several drug products containing the active ingredient valsartan, used to treat high blood pressure and heart failure. The recall is due to the presence of an impurity which is classified as a probable human carcinogen based on laboratory test results.
Take immediate action and review the Information about the recalled products on the FDA Drug Recalls website, including information on returning affected lots for credit. NCPA urges pharmacists to review their inventories for any of the products listed in the recall announcement. The FDA says that pharmacists should notify their patients if any of them have been dispensed the medicine included in this recall to discuss their treatment, which may include another valsartan product not affected by this recall or an alternative treatment option.
The FDA’s review is ongoing and has included investigating the levels of NDMA in the recalled products, assessing the possible effect on patients who have been taking them and what measures can be taken to reduce or eliminate the impurity from future batches produced by the company.
Filed under: General Problems
Leave a Reply